Registered Rwanda · Rwanda FDA

MYLOVASC 5 TABLETS

S-Amlodipine besilate 5mg

Rwanda FDA-HMP-MA-1055 Tablet 5mg

What it does

S-amlodipine is a medication used to help lower blood pressure and improve blood flow.

Commonly used for: high blood pressure (hypertension), chest pain (angina)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
Rwanda FDA-HMP-MA-1055
Registration date
28/02/2024
Expiry date
27/02/2029
Status
Registered
Active ingredient
S-Amlodipine besilate 5mg
Dosage form
Tablet
Strength
5mg
Pack size
3x10 Tablets
Therapeutic class
-
Manufacturer / MAH
Bafna Pharmaceuticals
Applicant / LTR
PRISMA PHARMA FZE
Country of origin
INDIA
Manufacturer location
1st floor, 68, Thambu Chetty St, Parry's Corner, George Town, Chennai, Tamil Nadu 600001, India

Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:19 · updated 2026-09-17 02:30:43

Disclaimer: This information is sourced from Rwanda Food and Drugs Authority (Rwanda). Always consult a qualified healthcare professional before using any medication.

About this medicine

S-amlodipine is a medication used to help lower blood pressure and improve blood flow.

What it treats

  • high blood pressure (hypertension)
  • chest pain (angina)

How it works

It relaxes and widens blood vessels, making it easier for the heart to pump blood.

Who it's for

It is for adults who need help managing their blood pressure or reducing chest pain.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: samlodipine

BNF-referenced

Samlodipine is a calcium channel blocker primarily used in the management of hypertension and angina pectoris. It functions by relaxing vascular smooth muscle and promoting vasodilation, thereby reducing blood pressure and improving blood flow to the heart. This drug is particularly effective in reducing peripheral vascular resistance, making it beneficial for patients with elevated blood pressure.

Indications

  • Hypertension
  • Angina pectoris

Dosage

Children: 1.25-2.5 mg once daily.

Adults: 2.5-5 mg once daily.

Mechanism of action

Levamlodipine blocks the transmembrane influx of calcium through L-type calcium channels into the vascular and cardiac smooth muscles. This results in vasodilation and a decrease in blood pressure. It inhibits calcium influx in vascular smooth muscle more significantly than in cardiac muscle, leading to decreased peripheral vascular resistance and lower blood pressure. Although in vitro studies have shown a negative inotropic effect, this is unlikely to be clinically relevant.

Pharmacodynamics

Levamlodipine inhibits L-type calcium channels in vascular smooth muscle, leading to reduced peripheral vascular resistance and blood pressure. It is administered once daily, and patients should be informed about potential side effects, including symptomatic hypotension, worsening angina, and myocardial infarction.

Pharmacokinetics

The pharmacokinetics of samlodipine include its absorption, distribution, metabolism, and excretion. It is generally well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring several hours after oral administration. The drug has a long elimination half-life, allowing for once-daily dosing. It is metabolized in the liver and excreted primarily through the kidneys.

Adverse effects

  • symptomatic hypotension
  • worsening angina
  • myocardial infarction

Pregnancy

Caution is advised, as safety during pregnancy has not been established.

Breast-feeding

Caution is advised, as it is not known if samlodipine is excreted in human milk.

Storage

Store at room temperature, away from direct sunlight and moisture.

Formulations

  • tablets

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: s-amlodipine

PubChem CID 9822750

Molecular formula: C20H25ClN2O5

Mechanism of action

Levamlodipine blocks the transmembrane influx of calcium through L-type calcium channels into the vascular and cardiac smooth muscles resulting in vasodilation and a subsequent decrease in blood pressure. Levamlodipine inhibits calcium influx in vascular smooth muscle to a greater degree than in cardiac muscle, leading to decreased peripheral vascular resistance and lowered blood pressure. In vitro studies have shown a negative inotropic effect but this is unlikely to be clinically relevant.

Pharmacodynamics

Levamlodipine inhibits L-type calcium channels in vascular smooth muscle, reducing peripheral vascular resistance and blood pressure. It is given once daily in doses of 1.25-2.5mg in children and 2.5-5mg in adults. Patients should be counselled regarding the risk of symptomatic hypotension, worsening angina, and myocardial infarction.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.